Ofev is an anti-fibrotic drug owned by Boehringer Ingelheim, first authorized for market use on 15 October, 2014. The active ingredient in Ofev is nintedanib esylate and it is available in capsule; oral dosage forms.
The generic version of Ofev might become available after 07 December, 2029. This is the expiration date of the last related patent (US9907756*PED), assuming no further extensions or litigation outcomes. The expected generic release could change due to Para IV filings by generic pharmaceutical manufacturers.
Ofev is used for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The effectiveness of Ofev is largely due to its active ingredient, nintedanib esylate.
Ofev has 9 active drug patents. The last of these, 'Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative' (US9907756*PED), is expected to expire on 07 December, 2029. An Ofev generic could become available after this date. Below are the details of the patent: